It uses a patient’s peripheral blood mononuclear cells (PBMCs) exposed to a fusion protein, PA2024, which combines an antigen from prostate cancer cells with an immune activator, GM-CSF, priming an immune response against prostate cancer cells expressing the antigen [151,152,153,154,155]. Here, CSF2 is linked to prostate carcinoma.